Plasmacytoid dendritic cells, a role in neoplastic prevention and progression

European Journal of Clinical Investigation

Volumn 45, Issue s1, 2015, Pages 1-8

  Lombardi, Vincent C ^a,b   Khaiboullina, Svetlana F ^a,b   Rizvanov, Albert A ^b  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^b KAZAN FEDERAL UNIVERSITY   (Russian Federation)

Author keywords

Cancer; Immunity; PDC; Plasmacytoid dendritic cells; Tolerance; Tumour

Indexed keywords

ADJUVANTS, IMMUNOLOGIC; AMINOQUINOLINES; CANCER VACCINES; IMIQUIMOD; TLR7 PROTEIN, HUMAN; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTORS;

AGONISTS; DENDRITIC CELLS; DISEASE PROGRESSION; HUMANS; IMMUNOLOGY; IMMUNOTHERAPY; MELANOMA; METHODS; NEOPLASMS; SKIN NEOPLASMS; T-LYMPHOCYTES; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

ADJUVANTS, IMMUNOLOGIC; AMINOQUINOLINES; CANCER VACCINES; DENDRITIC CELLS; DISEASE PROGRESSION; HUMANS; IMMUNOTHERAPY; MELANOMA; NEOPLASMS; SKIN NEOPLASMS; T-LYMPHOCYTES; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTORS; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84919331192     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12363     Document Type: Review

References (75)

1. Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999;284:1835-7.
2. Lombardi VC, Khaiboullina SF. Plasmacytoid dendritic cells of the gut: relevance to immunity and pathology. Clin Immunol 2014;153:165-77.
3. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004;303:1529-31.
4. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004;303:1526-9.
5. Kadowaki N, Antonenko S, Liu YJ. Distinct CpG DNA and polyinosinic-polycytidylic acid double-stranded RNA, respectively, stimulate CD11c- type 2 dendritic cell precursors and CD11c+ dendritic cells to produce type I IFN. J Immunol 2001;166:2291-5.
6. Kerkmann M, Rothenfusser S, Hornung V, Towarowski A, Wagner M, Sarris A et al. Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells. J Immunol 2003;170:4465-74.
7. Ruscanu S, Pascale F, Bourge M, Hemati B, Elhmouzi-Younes J, Urien C et al. The double-stranded RNA bluetongue virus induces type I interferon in plasmacytoid dendritic cells via a MYD88-dependent TLR7/8-independent signaling pathway. J Virol 2012;86:5817-28.
8. Hochrein H, O'Keeffe M, Wagner H. Human and mouse plasmacytoid dendritic cells. Hum Immunol 2002;63:1103-10.
9. Krug A, Rothenfusser S, Hornung V, Jahrsdorfer B, Blackwell S, Ballas ZK et al. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol 2001;31:2154-63.
10. Proietto AI, O'Keeffe M, Gartlan K, Wright MD, Shortman K, Wu L et al. Differential production of inflammatory chemokines by murine dendritic cell subsets. Immunobiology 2004;209:163-72.
11. Hellman P, Eriksson H. Early activation markers of human peripheral dendritic cells. Hum Immunol 2007;68:324-33.
12. Bizzarri M, Cucina A. Tumor and the microenvironment: a chance to reframe the paradigm of carcinogenesis? Biomed Res Int 2014;2014:934038.
13. Vosseler S, Mirancea N, Bohlen P, Mueller MM, Fusenig NE. Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants. Cancer Res 2005;65:1294-305.
14. Barcellos-Hoff MH, Ravani SA. Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res 2000;60:1254-60.
15. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001;193:727-40.
16. Kao J, Houck K, Fan Y, Haehnel I, Libutti SK, Kayton ML et al. Characterization of a novel tumor-derived cytokine. Endothelial-monocyte activating polypeptide II. J Biol Chem 1994;269:25106-19.
17. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004;4:540-50.
18. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010;141:39-51.
19. Zaynagetdinov R, Sherrill TP, Polosukhin VV, Han W, Ausborn JA, McLoed AG et al. A critical role for macrophages in promotion of urethane-induced lung carcinogenesis. J Immunol 2011;187:5703-11.
20. Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 2006;203:871-81.
21. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9.
22. Mizukami Y, Kono K, Kawaguchi Y, Akaike H, Kamimura K, Sugai H et al. CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer. Int J Cancer 2008;122:2286-93.
23. Huang XM, Liu XS, Lin XK, Yu H, Sun JY, Liu XK et al. Role of plasmacytoid dendritic cells and inducible costimulator-positive regulatory T cells in the immunosuppression microenvironment of gastric cancer. Cancer Sci 2014;105:150-8.
24. Faget J, Bendriss-Vermare N, Gobert M, Durand I, Olive D, Biota C et al. ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells. Cancer Res 2012;72:6130-41.
25. Shortman K, Naik SH. Steady-state and inflammatory dendritic-cell development. Nat Rev Immunol 2007;7:19-30.
26. Villadangos JA, Schnorrer P. Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat Rev Immunol 2007;7:543-55.
27. Salio M, Cella M, Vermi W, Facchetti F, Palmowski MJ, Smith CL et al. Plasmacytoid dendritic cells prime IFN-gamma-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions. Eur J Immunol 2003;33:1052-62.
28. Hartmann E, Wollenberg B, Rothenfusser S, Wagner M, Wellisch D, Mack B et al. Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res 2003;63:6478-87.
29. Zou W, Machelon V, Coulomb-L'Hermin A, Borvak J, Nome F, Isaeva T et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 2001;7:1339-46.
30. Treilleux I, Blay JY, Bendriss-Vermare N, Ray-Coquard I, Bachelot T, Guastalla JP et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res 2004;10:7466-74.
31. Palamara F, Meindl S, Holcmann M, Luhrs P, Stingl G, Sibilia M. Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod. J Immunol 2004;173:3051-61.
32. Vermi W, Bonecchi R, Facchetti F, Bianchi D, Sozzani S, Festa S et al. Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J Pathol 2003;200:255-68.
33. Conrad C, Gregorio J, Wang YH, Ito T, Meller S, Hanabuchi S et al. Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(+) T-regulatory cells. Cancer Res 2012;72:5240-9.
34. Aspord C, Leccia MT, Charles J, Plumas J. Plasmacytoid dendritic cells support melanoma progression by promoting Th2 and regulatory immunity through OX40L and ICOSL. Cancer Immunol Res 2013;1:402-15.
35. Charles J, Di Domizio J, Salameire D, Bendriss-Vermare N, Aspord C, Muhammad R et al. Characterization of circulating dendritic cells in melanoma: role of CCR6 in plasmacytoid dendritic cell recruitment to the tumor. J Invest Dermatol 2010;130:1646-56.
36. Rollins BJ. Chemokines. Blood 1997;90:909-28.
37. Tilton B, Ho L, Oberlin E, Loetscher P, Baleux F, Clark-Lewis I et al. Signal transduction by CXC chemokine receptor 4. Stromal cell-derived factor 1 stimulates prolonged protein kinase B and extracellular signal-regulated kinase 2 activation in T lymphocytes. J Exp Med 2000;192:313-24.
38. Le Borgne M, Etchart N, Goubier A, Lira SA, Sirard JC, van Rooijen N, et al. Dendritic cells rapidly recruited into epithelial tissues via CCR6/CCL20 are responsible for CD8+ T cell crosspriming in vivo. Immunity 2006;24:191-201.
39. Le Mercier I, Poujol D, Sanlaville A, Sisirak V, Gobert M, Durand I et al. Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment. Cancer Res 2013;73:4629-40.
40. Labidi-Galy SI, Treilleux I, Goddard-Leon S, Combes JD, Blay JY, Ray-Coquard I et al. Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis. Oncoimmunology 2012;1:380-2.
41. Faget J, Sisirak V, Blay JY, Caux C, Bendriss-Vermare N, Menetrier-Caux C. ICOS is associated with poor prognosis in breast cancer as it promotes the amplification of immunosuppressive CD4 T cells by plasmacytoid dendritic cells. Oncoimmunology 2013;2:e23185.
42. Perrot I, Blanchard D, Freymond N, Isaac S, Guibert B, Pacheco Y et al. Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J Immunol 2007;178:2763-9.
43. Beckebaum S, Zhang X, Chen X, Yu Z, Frilling A, Dworacki G et al. Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets. Clin Cancer Res 2004;10:7260-9.
44. Saulep-Easton D, Vincent FB, Le Page M, Wei A, Ting SB, Croce CM et al. Cytokine-driven loss of plasmacytoid dendritic cell function in chronic lymphocytic leukemia. Leukemia 2014;28:2005-15.
45. Jensen TO, Schmidt H, Moller HJ, Donskov F, Hoyer M, Sjoegren P et al. Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. Cancer 2012;118:2476-85.
46. O'Donnell RK, Mick R, Feldman M, Hino S, Wang Y, Brose MS et al. Distribution of dendritic cell subtypes in primary oral squamous cell carcinoma is inconsistent with a functional response. Cancer Lett 2007;255:145-52.
47. Sisirak V, Vey N, Goutagny N, Renaudineau S, Malfroy M, Thys S et al. Breast cancer-derived transforming growth factor-beta and tumor necrosis factor-alpha compromise interferon-alpha production by tumor-associated plasmacytoid dendritic cells. Int J Cancer 2013;133:771-8.
48. Tsukamoto N, Okada S, Onami Y, Sasaki Y, Umezawa K, Kawakami Y. Impairment of plasmacytoid dendritic cells for IFN production by the ligand for immunoglobulin-like transcript 7 expressed on human cancer cells. Clin Cancer Res 2009;15:5733-43.
49. McCarty MF, Bielenberg D, Donawho C, Bucana CD, Fidler IJ. Evidence for the causal role of endogenous interferon-alpha/beta in the regulation of angiogenesis, tumorigenicity, and metastasis of cutaneous neoplasms. Clin Exp Metastasis 2002;19:609-15.
50. Watkins SK, Zhu Z, Riboldi E, Shafer-Weaver KA, Stagliano KE, Sklavos MM et al. FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J Clin Invest 2011;121:1361-72.
51. Sharma MD, Baban B, Chandler P, Hou DY, Singh N, Yagita H et al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2, 3-dioxygenase. J Clin Invest 2007;117:2570-82.
52. Ito T, Yang M, Wang YH, Lande R, Gregorio J, Perng OA et al. Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. J Exp Med 2007;204:105-15.
53. Munn DH, Mellor AL. Indoleamine 2, 3-dioxygenase and tumor-induced tolerance. J Clin Invest 2007;117:1147-54.
54. Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ et al. Expression of indoleamine 2, 3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 2004;114:280-90.
55. Preynat-Seauve O, Schuler P, Contassot E, Beermann F, Huard B, French LE. Tumor-infiltrating dendritic cells are potent antigen-presenting cells able to activate T cells and mediate tumor rejection. J Immunol 2006;176:61-7.
56. Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens ML. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999;41:1002-7.
57. Urosevic M, Dummer R, Conrad C, Beyeler M, Laine E, Burg G et al. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst 2005;97:1143-53.
58. van Egmond S, Hoedemaker C, Sinclair R. Successful treatment of perianal Bowen's disease with imiquimod. Int J Dermatol 2007;46:318-9.
59. Tel J, Anguille S, Waterborg CE, Smits EL, Figdor CG, de Vries IJ. Tumoricidal activity of human dendritic cells. Trends Immunol 2014;35:38-46.
60. Larmonier N, Fraszczak J, Lakomy D, Bonnotte B, Katsanis E. Killer dendritic cells and their potential for cancer immunotherapy. Cancer Immunol Immunother 2010;59:1-11.
61. Veugelers K, Motyka B, Goping IS, Shostak I, Sawchuk T, Bleackley RC. Granule-mediated killing by granzyme B and perforin requires a mannose 6-phosphate receptor and is augmented by cell surface heparan sulfate. Mol Biol Cell 2006;17:623-33.
62. Bratke K, Nielsen J, Manig F, Klein C, Kuepper M, Geyer S et al. Functional expression of granzyme B in human plasmacytoid dendritic cells: a role in allergic inflammation. Clin Exp Allergy 2010;40:1015-24.
63. Tel J, Smits EL, Anguille S, Joshi RN, Figdor CG, de Vries IJ. Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities. Blood 2012;120:3936-44.
64. Stary G, Bangert C, Tauber M, Strohal R, Kopp T, Stingl G. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med 2007;204:1441-51.
65. Kalb ML, Glaser A, Stary G, Koszik F, Stingl G. TRAIL(+) human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod- and IFN-alpha-mediated antitumor reactivity. J Immunol 2012;188:1583-91.
66. Drobits B, Holcmann M, Amberg N, Swiecki M, Grundtner R, Hammer M et al. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J Clin Invest 2012;122:575-85.
67. Anichini A, Fossati G, Parmiani G. Clonal analysis of cytotoxic T-lymphocyte response to autologous human metastatic melanoma. Int J Cancer 1985;35:683-9.
68. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-4.
69. Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008;14:3044-51.
70. Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol 2013;31:4199-206.
71. Dennis LK. Analysis of the melanoma epidemic, both apparent and real: data from the 1973 through 1994 surveillance, epidemiology, and end results program registry. Arch Dermatol 1999;135:275-80.
72. Robert C, Thomas L, Bondarenko I, O'Day S, M DJ, Garbe C et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26.
73. Kono K. Current status of cancer immunotherapy. J Stem Cells Regen Med 2014;10:8-13.
74. Tel J, Aarntzen EH, Baba T, Schreibelt G, Schulte BM, Benitez-Ribas D et al. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res 2013;73:1063-75.
75. Kim A, Noh YW, Kim KD, Jang YS, Choe YK, Lim JS. Activated natural killer cell-mediated immunity is required for the inhibition of tumor metastasis by dendritic cell vaccination. Exp Mol Med 2004;36:428-43.